Correction to: Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms
Infect Dis Ther
.
2022 Aug;11(4):1459-1460.
doi: 10.1007/s40121-022-00660-6.
Authors
Joe Yang
1
,
Jaesh Naik
2
,
Matthew Massello
2
,
Lewis Ralph
2
,
Ryan James Dillon
3
Affiliations
1
Merck & Co., Inc., Kenilworth, NJ, USA.
2
BresMed Health Solutions Ltd, Sheffield, UK.
3
Merck & Co., Inc., Kenilworth, NJ, USA. ryan.dillon@merck.com.
PMID:
35749011
PMCID:
PMC9334491
DOI:
10.1007/s40121-022-00660-6
No abstract available
Publication types
Published Erratum